Triple Agonist Peptide (GLP-1 / GIP / Glucagon) | Fat Loss, Metabolic Control & Glycaemic Support | For Research Use Only

Retatrutide is an advanced investigational peptide that simultaneously targets GLP-1, GIP, and Glucagon receptors, representing a revolutionary step in metabolic research. Its multi-pathway activity leads to superior effects on body weight reduction, insulin sensitivity, and caloric expenditure compared to earlier GLP-1 agonists like Semaglutide and Tirzepatide.

This mid-range 36mg format is ideal for researchers seeking precise titration in long-term metabolic and obesity-related studies.

🔍 Key Features

• Triple Receptor Activation (GLP-1 + GIP + Glucagon)

• Clinically Proven Weight Loss Effects in Early Trials

• Suppresses Appetite and Enhances Fat Oxidation

• Improves Glucose Tolerance & Insulin Sensitivity

• Potential in Obesity, Type 2 Diabetes & NASH Models

• Once-Weekly Research Protocols with Long Half-Life

⚙️ Compound Details

• Compound Name: Retatrutide

• CAS Number: 2381089-83-2

• Molecular Formula: C₂₀₉H₃₂₉N₅₅O₆₆

• Molecular Weight: ~4717.35 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 36mg per vial

🧊 Storage & Handling

• Storage (lyophilised): –20°C, dry and light-protected

• Reconstitution: Use sterile bacteriostatic water (1–2ml recommended)

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Direct light, heat exposure, and repeated freeze-thaw cycles

⚠️ For Research Use Only

Retatrutide – 36mg is provided exclusively for preclinical and laboratory research. It is not for human consumption, therapeutic use, or diagnostic application. To be handled by licensed professionals only.